News Snapshot:
AstraZeneca Signs First COVID-19 Vaccine Deal with China's Shenzhen Kangtai By Mark Terry AstraZeneca signed a deal with Beijing-based Shenzhen Kangtai Biological Products to manufacture AstraZeneca and the University of Oxford’s COVID-19 vaccine in mainland China. Shenzhen Kangtai is one of the top Chinese vaccine manufacturers. Under the agreement, Shenzhen Kangtai will ensure annual production capacity of at least 100 million doses of AZD1222, the experimental COVID-19 vaccine, by the end of this year. Shenzhen Kangtai has capacity to manufacture at least 200 million by the end of next year as part of the deal. They will also discuss the...
